ArticleBMJ open2024

Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study).

Yu-Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.